Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL231 vs Ultibro in COPD
NCT06619210Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HL231 Solution for Inhalation in chronic obstructive pulmonary disease (COPD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Jan 2022; status: completed.
02
Drugs
HL231 Solution for Inhalation
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06619210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619210.